{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:09:09Z","timestamp":1793664549674,"version":"4.5.1"},"reference-count":102,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.autrev.2025.103853","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T10:11:21Z","timestamp":1749982281000},"page":"103853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical features, pathogenesis, and treatment of inflammatory bowel disease-associated spondyloarthritis"],"prefix":"10.1016","volume":"24","author":[{"given":"Mitsuhiro","family":"Akiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Shimanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103853_bb0005","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41584-023-00984-8","article-title":"Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies","volume":"19","author":"Cozzi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0010","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s10067-014-2768-y","article-title":"Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis","volume":"34","author":"Seo","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0015","first-page":"631","article-title":"The prevalence and incidence of axial and peripheral Spondyloarthritis in inflammatory bowel disease: a systematic review and Meta-analysis","volume":"11","author":"Karreman","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2025.103853_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001777","article-title":"Spondyloarthritis in inflammatory bowel disease cohorts: systematic literature review and critical appraisal of study designs","volume":"8","author":"Schwartzman","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103853_bb0025","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.3390\/jcm13154540","article-title":"Enthesitis in IBD patients","volume":"13","author":"Akrapovic Olic","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2025.103853_bb0030","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1080\/00365521.2018.1518482","article-title":"Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study","volume":"53","author":"Ossum","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2025.103853_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.637459","article-title":"High prevalence of ultrasound verified enthesitis in patients with inflammatory bowel disease with or without spondylarthritis","volume":"8","author":"Husic","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.autrev.2025.103853_bb0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00296-022-05208-y","article-title":"Screening for spondyloarthritis in patients with inflammatory bowel diseases","volume":"43","author":"Ottaviani","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2025.103853_bb0045","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s40744-024-00709-7","article-title":"The challenge of IBD-related arthritis screening questionnaires in early and predominantly Entheseal phenotypes","volume":"11","author":"Zabotti","year":"2024","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.autrev.2025.103853_bb0050","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14309\/ajg.0000000000003039","article-title":"Spine and sacroiliac joint involvement in newly diagnosed patients with inflammatory bowel disease: clinical and MRI findings from a population-based cohort","volume":"120","author":"Vladimirova","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2025.103853_bb0055","article-title":"Comparing clinical profiles in spondyloarthritis with Crohn\u2019s disease or ulcerative colitis: insights from the ASAS-PerSpA study","volume":"8","author":"Rodriguez","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.autrev.2025.103853_bb0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.42.3.387","article-title":"Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history","volume":"42","author":"Orchard","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2025.103853_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105367","article-title":"Presence of spondyloarthritis associated to higher disease activity and HLA-B27 positivity in patients with early Crohn\u2019s disease: clinical and MRI results from a prospective inception cohort","volume":"89","author":"Rios Rodriguez","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2025.103853_bb0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.autrev.2015.11.002","article-title":"Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients","volume":"15","author":"Conigliaro","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103853_bb0075","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/ecco-jcc\/jjaa096","article-title":"The IBIS-Q [IBd identification of Spondyloarthritis questionnaire]: a novel tool to detect both axial and peripheral arthritis in inflammatory bowel disease patients","volume":"14","author":"Variola","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2025.103853_bb0080","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s10067-017-3937-6","article-title":"The DETection of arthritis in inflammatory boweL diseases (DETAIL) questionnaire: development and preliminary testing of a new tool to screen patients with inflammatory bowel disease for the presence of spondyloarthritis","volume":"37","author":"Di Carlo","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3899\/jrheum.200364","article-title":"Multicenter validation of the DETAIL questionnaire for the screening of spondyloarthritis in patients with inflammatory bowel diseases","volume":"48","author":"Benfaremo","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0090","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.semarthrit.2020.01.001","article-title":"Ultrasonographic and clinical assessment of peripheral enthesitis and arthritis in an Italian cohort of inflammatory bowel disease patients","volume":"50","author":"Bertolini","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103853_bb0095","article-title":"Musculoskeletal ultrasound to identify subclinical joint and periarticular involvement in patients with inflammatory bowel disease: a systematic literature review","volume":"9","author":"Sakellariou","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2025.103853_bb0100","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1093\/rheumatology\/keaa320","article-title":"Ultrasound subclinical musculoskeletal findings in inflammatory bowel disease: diagnostic value of positive Doppler signal","volume":"59","author":"Rodr\u00edguez-Caminero","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103853_bb0105","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/1573397119666230529105122","article-title":"Early identification of Sacroiliitis in patients with suspected Spondyloarthritis: a challenging task","volume":"19","author":"Nessib","year":"2023","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.autrev.2025.103853_bb0110","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1148\/radiol.2020201537","article-title":"MRI-based synthetic CT in the detection of structural lesions in patients with suspected Sacroiliitis: comparison with MRI","volume":"298","author":"Jans","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.autrev.2025.103853_bb0115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejr.2023.10.001","article-title":"Screening of silent inflammatory bowel disease in seronegative spondyloarthritis patients: fecal calprotectin, ileo-colonoscopy and histopathology assessment","volume":"46","author":"Badran","year":"2024","journal-title":"Egypt Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0120","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3899\/jrheum.161216","article-title":"Detection of Crohn disease in patients with spondyloarthropathy: the SpACE capsule study","volume":"45","author":"Kopylov","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0125","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/1756-185X.14388","article-title":"Fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis","volume":"25","author":"Campos","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0130","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00296-022-05117-0","article-title":"Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis","volume":"42","author":"Ono","year":"2022","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.autrev.2025.103853_bb0135","doi-asserted-by":"crossref","DOI":"10.4081\/reumatismo.2024.1770","article-title":"Inflammatory bowel diseases and spondyloarthritis: a focus on female patients","volume":"76","author":"Caranfil","year":"2024","journal-title":"Reumatismo"},{"key":"10.1016\/j.autrev.2025.103853_bb0140","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The assessment of SpondyloArthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0150","doi-asserted-by":"crossref","first-page":"e805","DOI":"10.1016\/S2665-9913(24)00132-2","article-title":"Arthritis complicating inflammatory bowel disease- the future is now","volume":"6","author":"Song","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0155","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1093\/rheumatology\/keaa036","article-title":"Clinical and sonographic discrimination between fibromyalgia and spondyloarthopathy in inflammatory bowel disease with musculoskeletal pain","volume":"59","author":"Martinis","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103853_bb0160","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/AJP.0000000000000698","article-title":"Musculoskeletal pain in individuals with inflammatory bowel disease reflects three distinct profiles","volume":"35","author":"Falling","year":"2019","journal-title":"Clin J Pain"},{"key":"10.1016\/j.autrev.2025.103853_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105454","article-title":"Involvement of Mediterranean fever gene mutations in colchicine-responsive enterocolitis: a retrospective cohort study","volume":"110","author":"Nakase","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.autrev.2025.103853_bb0170","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/ajg.2010.95","article-title":"Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis","volume":"105","author":"J\u00fcrgens","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2025.103853_bb0175","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/hmg\/ddac241","article-title":"Case-case genome-wide association analysis identifying genetic loci with divergent effects on Crohn\u2019s disease and ulcerative colitis","volume":"32","author":"Jung","year":"2023","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.autrev.2025.103853_bb0180","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/08916934.2022.2076837","article-title":"Associations between IL-23R gene polymorphism (rs10889677 a\/C) and ankylosing spondylitis and rheumatoid arthritis susceptibility: a meta-analysis with trial sequential analysis","volume":"55","author":"Zhang","year":"2022","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2025.103853_bb0185","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","article-title":"Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model","volume":"72","author":"Van Praet","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0190","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/BOR.0000000000000239","article-title":"Subclinical gut inflammation in ankylosing spondylitis","volume":"28","author":"Ciccia","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13075-017-1223-2","article-title":"A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis","volume":"19","author":"Klingberg","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103853_bb0200","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1053\/j.gastro.2020.08.005","article-title":"Increased intestinal permeability is associated with later development of Crohn\u2019s disease","volume":"159","author":"Turpin","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2025.103853_bb0205","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1053\/j.gastro.2022.07.004","article-title":"Altered gut microbiome composition and function are associated with gut barrier dysfunction in healthy relatives of patients with Crohn\u2019s disease","volume":"163","author":"Leibovitzh","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2025.103853_bb0210","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1053\/j.gastro.2017.05.056","article-title":"Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing","volume":"153","author":"Chang","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2025.103853_bb0215","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-019-0258-z","article-title":"Gut microbiota-derived metabolites as key actors in inflammatory bowel disease","volume":"17","author":"Lavelle","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0220","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00281-021-00844-1","article-title":"Microbial-derived antigens and metabolites in spondyloarthritis","volume":"43","author":"Yang","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.autrev.2025.103853_bb0225","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s13075-019-2018-4","article-title":"A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103853_bb0230","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1128\/mSystems.00176-18","article-title":"Altered bacterial-fungal Interkingdom networks in the guts of ankylosing spondylitis patients","volume":"4","author":"Li","year":"2019","journal-title":"mSystems"},{"key":"10.1016\/j.autrev.2025.103853_bb0235","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/annrheumdis-2016-210000","article-title":"Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis","volume":"76","author":"Ciccia","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0240","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2464221","article-title":"IgG-seq identifies immune-reactive enteric bacteria in Crohn\u2019s disease with spondyloarthritis","volume":"17","author":"Maldarelli","year":"2025","journal-title":"Gut Microbes"},{"key":"10.1016\/j.autrev.2025.103853_bb0245","first-page":"2269","article-title":"Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23\/IFN-gamma axis","volume":"118","author":"Kamada","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103853_bb0250","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/01.MIB.0000442014.52661.20","article-title":"Interleukin 23 in Crohn\u2019s disease","volume":"20","author":"Eken","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0255","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.24389","article-title":"Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis","volume":"60","author":"Ciccia","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103853_bb0260","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/annrheumdis-2018-214944","article-title":"Identification of myeloid cells in the human enthesis as the main source of local IL-23 production","volume":"78","author":"Bridgewood","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0265","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/art.40150","article-title":"Brief report: group 3 innate lymphoid cells in human Enthesis","volume":"69","author":"Cuthbert","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0270","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0275","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103853_bb0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41467-018-07911-6","article-title":"ROR\u03b3t inhibition selectively targets IL-17 producing iNKT and \u03b3\u03b4-T cells enriched in Spondyloarthritis patients","volume":"10","author":"Venken","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103853_bb0285","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/art.42090","article-title":"Characterization of blood mucosal-associated invariant T cells in patients with axial Spondyloarthritis and of resident mucosal-associated invariant T cells from the axial Entheses of non-axial Spondyloarthritis control patients","volume":"74","author":"Rosine","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0290","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.3390\/ijms22147618","article-title":"Innate lymphoid cells in intestinal homeostasis and inflammatory bowel disease","volume":"22","author":"Saez","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103853_bb0295","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13412","article-title":"Dysregulation of T cell response in the pathogenesis of inflammatory bowel disease","volume":"100","author":"Chandwaskar","year":"2024","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2025.103853_bb0300","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/intimm\/dxab070","article-title":"Characteristics of mucosal-associated invariant T cells and their roles in immune diseases","volume":"33","author":"Chiba","year":"2021","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2025.103853_bb0305","first-page":"1085","article-title":"Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis","volume":"34","author":"Triggianese","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0310","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1053\/gast.2000.20173","article-title":"Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy","volume":"119","author":"May","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2025.103853_bb0315","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/rheumatology\/key267","article-title":"Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease","volume":"58","author":"Dubash","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103853_bb0320","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/rheumatology\/kez056","article-title":"Comment on: emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease","volume":"58","author":"Alivernini","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103853_bb0325","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2025.103853_bb0330","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/rheumatology\/keac391","article-title":"Disease-specific expansion of CD29+IL-17RA+ T effector cells possessing multiple signalling pathways in spondyloarthritis","volume":"62","author":"Akiyama","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103853_bb0335","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.4049\/jimmunol.178.7.4506","article-title":"Collagen distribution and expression of collagen-binding alpha1beta1 (VLA-1) and alpha2beta1 (VLA-2) integrins on CD4 and CD8 T cells during influenza infection","volume":"178","author":"Richter","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103853_bb0340","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/annrheumdis-2019-215349","article-title":"Integrin and transcriptomic profiles identify a distinctive synovial CD8+ T cell subpopulation in spondyloarthritis","volume":"78","author":"Qaiyum","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0345","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.immuni.2016.07.007","article-title":"A high-dimensional atlas of human T cell diversity reveals tissue-specific trafficking and cytokine signatures","volume":"45","author":"Wong","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2025.103853_bb0350","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1136\/annrheumdis-2016-209749","article-title":"Clinical efficacy of \u03b14 integrin block with natalizumab in ankylosing spondylitis","volume":"75","author":"Ciccia","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0355","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/00365521.2014.966753","article-title":"Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease","volume":"50","author":"Kvasnovsky","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2025.103853_bb0360","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of Ustekinumab in axial Spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0365","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/imt-2022-0197","article-title":"Ustekinumab in enteropathic arthritis","volume":"15","author":"Ulusoy","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.autrev.2025.103853_bb0370","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103853_bb0375","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103853_bb0380","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.3748\/wjg.v23.i39.7139","article-title":"Adalimumab efficacy in enteropathic spondyloarthritis: a 12-mo observational multidisciplinary study","volume":"23","author":"Luchetti","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2025.103853_bb0385","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/ard.2003.012450","article-title":"Infliximab in spondyloarthropathy associated with Crohn\u2019s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations","volume":"63","author":"Generini","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0390","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard.62.1.74","article-title":"Efficacy of etanercept for treatment of Crohn\u2019s related spondyloarthritis but not colitis","volume":"62","author":"Marzo-Ortega","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0395","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025122","article-title":"Two years follow-up of golimumab treatment in refractory enteropathic spondyloarthritis patients with Crohn disease: a STROBE-compliant study","volume":"100","author":"Conigliaro","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2025.103853_bb0400","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0405","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1097\/MCG.0000000000001608","article-title":"Effectiveness and safety of Tofacitinib for ulcerative colitis: systematic review and Meta-analysis","volume":"56","author":"Taneja","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2025.103853_bb0410","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/mrcr\/rxac021","article-title":"Effect of tofacitinib in a patient with inflammatory bowel disease-related arthritis","volume":"6","author":"Lomborg","year":"2022","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.autrev.2025.103853_bb0415","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2217\/imt-2022-0110","article-title":"Tofacitinib experience in patients with enteropathic arthritis","volume":"15","author":"Da\u011fl\u0131","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.autrev.2025.103853_bb0420","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13256-023-03796-2","article-title":"Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports","volume":"17","author":"Momen Majumder","year":"2023","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.autrev.2025.103853_bb0425","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000226","article-title":"Use of Tofacitinib for the treatment of arthritis associated with ulcerative colitis","volume":"6","author":"Wang","year":"2019","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.autrev.2025.103853_bb0430","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"Study A3921043 investigators. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0435","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2025.103853_bb0440","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103853_bb0445","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/msc.1802","article-title":"Clinical efficacy of JAK inhibitors on enthesitis in spondyloarthropathy: a scoping literature review","volume":"21","author":"Jubber","year":"2023","journal-title":"Musculoskeletal Care"},{"key":"10.1016\/j.autrev.2025.103853_bb0450","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of Upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2025.103853_bb0455","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0460","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103853_bb0465","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103853_bb0470","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103853_bb0475","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1007\/s00296-024-05735-w","article-title":"Successful treatment of Crohn\u2019s disease-related peripheral spondyloarthritis with upadacitinib: two case reports and case-based review","volume":"44","author":"Suzuki","year":"2024","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2025.103853_bb0480","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3899\/jrheum.2024-0055","article-title":"Potential efficacy of Janus kinase inhibitors in the treatment of a patient with coexisting peripheral and axial Spondyloarthritis and ulcerative colitis","volume":"51","author":"Ishigaki","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0485","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103853_bb0490","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103853_bb0495","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103853_bb0500","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An Oral Interleukin-23-receptor antagonist peptide for plaque psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103853_bb0505","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the TYK2\/JAK1 inhibitor Brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103853_bb0510","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral Ritlecitinib and Brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T03:06:48Z","timestamp":1754795208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":102,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1568997225001132"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103853","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features, pathogenesis, and treatment of inflammatory bowel disease-associated spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103853","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103853"}}